Astrantus’s Labcorp LH Stock Holding History

Astrantus’s Portfolio LH Stock Details LH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$395K	Sell	1,746 -2,276	-57%	-$535K	0.66%	56
2021 Q4	$1.09M	Buy	+4,022	New	+$996K	0.81%	32

Other funds holding LH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Astrantus's LH Position: Q1 2022 in Review

Astrantus reduced its Labcorp (LH) stake by 57% in Q1 2022, selling an estimated $535K and leaving 1,746 shares worth $395K. The position accounts for 0.66% of the portfolio, ranked #56.

Astrantus first reported a position in LH in Q4 2021 and has held it in 2 quarters since. The position peaked at $1.09M in Q4 2021. 1,033 funds tracked by Wall St. Rank hold LH as of Q1 2022.

Astrantus held 1,746 shares of Labcorp worth $395K as of Q1 2022.
Astrantus sold 2,276 Labcorp shares in Q1 2022, an estimated $535K.
Labcorp made up 0.66% of Astrantus's portfolio in Q1 2022, its #56 holding.
Astrantus first reported a position in Labcorp in Q4 2021 and has held it in 2 quarters since.
Astrantus's Labcorp position peaked at $1.09M in Q4 2021.
1,033 funds tracked by Wall St. Rank held Labcorp as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.